---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032189"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:20:08.649492+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma Q2 net loss $5.7M ($0.02/sh); signs non-binding MAT2203 term sheet

## Summary
- Net loss for Q2 2024 was $5.7 million ($0.02 per share), compared to $6.1 million ($0.03) in Q2 2023.
- Cash, cash equivalents and marketable securities were $14.3 million as of June 30, 2024; raised $10M in April offering.
- Signed non-binding term sheet for global licensing rights to develop and commercialize oral MAT2203 for invasive aspergillosis.
- 31 patients enrolled in MAT2203 Compassionate/Expanded Use Access Program; 7 additional under evaluation.
- LNC platform showed tumor inhibition in animal models; additional optimization needed before selecting product candidate.

## SEC filing metadata
- accession: 0001493152-24-032189
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315224032189/0001493152-24-032189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315224032189/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032189
- JSON: https://secwatch.observer/filing/0001493152-24-032189.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.